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C3 Glomerulonephritis versus “C3 Glomerulopathies?” 
T. Keefe Davis M.D., FAAP 
 
Background and epidemiology 
C3 glomerulonephritis (C3Gn) is a due to abnormal regulation of the alternative 
complement pathway.  The diagnosis is based upon kidney biopsy immunofluorescences 
studies showing isolated or dominant C3 deposition within the glomerulus with little or no 
immunoglobulin deposition.1  It is a distinct entity from the other 4 classes of glomerulonephritis 
(Gn): immune complex, pauci-immune, antiglomerular basement membrane antibody, and 
monoclonal Gn.2  One caveat to immune complex disease is that there is a subset of patients 
with atypical post infectious glomerulonephritis who have persistent lab abnormalities (low C3, 
proteinuria, or elevated creatinine).  Patients with an atypical post infectious course may have 
C3Gn.  
The cause of C3Gn is excessive activation of the alternative complement pathway.  The 
primary defect is increased activity of the C3 and C5 convertases.3 One mechanism underlying 
the increased activity of these convertases is the development of a stabilizing autoantibody 
called C3 nephritic factor (C3NF).  Indeed, C3 nephritic factor hinders the breakdown of C3 
convertase, allowing it to continue to amplify the cascade resulting in increased production of 
C3 and by also generating the C5 convertase which itself initiates the membrane attack 
complex.4  The other mechanism responsible for increased activity of the C3 convertase is the 
loss of factor H functionality.  Since the normal function of factor H is to inhibit the C3 
convertase, mutations or acquired loss of the ability of factor H to regulate activated C3 results 
in excessive convergence towards assembly of the membrane attack complex.4 
C3 glomerulonephritis is a pediatric disease and rates of diagnosis are increasing with greater 
awareness of this distinct and separate entity from dense deposit disease (DDD), both of which 
are commonly classified under the broad heading of C3 glomerulopathies (Table 1).3,5,6  
Unfortunately, the classification of both C3Gn and DDD as C3 glomerulopathies adds confusion 
to the classification schema due to subtleties in the nomenclature. 
Table 1.  C3 Glomerulopathies:  Comparing and Contrasting Dense Deposit Disease versus C3 
Glomerulonephritis.  
Descriptive Factor Dense Deposit Disease C3 Glomerulonephritis 
Pathophysiology Abnormal regulation of the 
alternative complement 
pathway 
Abnormal regulation of the 
alternative complement 
pathway 
Light microscopy findings Almost always a 
membranoproliferative 
glomerulonephritis pattern 
Any pattern 
Immunofluorescence findings Dominant C3 staining Dominant C3 staining 
Electron microscopy Linear electron dense material 
within in the glomerular 
basement membrane 
(intramembranous) 
 
Dense deposits 
Subendothelial, subepithelial 
and/or mesangial electron-
dense deposits ;  
Lighter density deposits 
Age of affected Children and young adults; 
over half will be < 16 years of 
age at diagnosis. 
Children and young adults; 
about a quarter will be < 16 
years of age at diagnosis. 
C3 nephritic factor Present 80% of the time Present 40% of the time 
Serum C3 level >80% have low C3 levels Approx. 50% have low C3 
levels 
Soluble C5b-9 level Elevated in 9% Elevated in 50% 
Pathological gene variant Identified in 25% Identified in 25% 
Dysregulation of alternative Favors dysregulation of the Favors dysregulation of the 
pathway convertase C3 convertase C5 convertase 
Extrarenal abnormalities Drusen deposition in Bruch’s 
membrane of the retina 
(macular deposits) 
 
Risk of end stage kidney 
disease (ESKD) 
Approx. 70% progress to 
ESKD 
Approx. 35% progress to 
ESKD 
Risk of recurrence after 
kidney transplant 
>50% (100% in some studies) >50% 
 
Presentation 
The presentation of C3Gn is variable, but urine abnormalities are always present.  Most 
patients with C3Gn present with nephrotic range proteinuria and/or nephrotic syndrome and 
hematuria. Cases presenting with subnephrotic range proteinuria or isolated gross hematuria 
have been reported.  The clinician cannot use serum C3 levels or other blood work as a 
discerning factor from other forms of GN.3 Therefore, a kidney biopsy is required to establish the 
diagnosis.5  Although most biopsies of C3Gn show a membranoproliferative pattern, this is not 
required.  Immunofluorescence (IF) must show dominant C3 glomerular staining in the 
mesangium and  capillary loops that is at least 2+ stronger than other IF stains.2  Electron 
microscopy helps differentiate from DDD with C3Gn, with the latter showing lighter mesangial, 
subendothelial, or epithelial deposits rather than intramembranous linear dense deposits 
diagnostic of DDD.  
Diagnosis and Patient Management 
C3Gn is a rare disease with an incidence of 1-2 million/year (Table 2).5 Therefore, due to 
lack of clinical experience, a standard causative work up/approach cannot be recommended.  
However, based upon our current understanding of the pathophysiology (over activity of the 
alternative complement pathway) evaluation may require genetic testing for mutations in 
alternative complement proteins and measurement of autoantibodies (Table 3).3,7  
Table 2. Incidence of Pediatric Nephrology Conditions 
Disease/Condition Incidence 
C3 Glomerulonephritis 1-2 per million 
Dense Deposit Disease 1-2 per million 
Autosomal Dominant 
Polycystic Kidney Disease 
1 per 1,000 
Autosomal Recessive 
Polycystic Kidney Disease 
1 per 40,000 
Immunoglobulin A 
Nephropathy 
3 per 100,000 
Nephrotic Syndrome 4 per 100,000 
Pediatric End Stage Kidney 
Disease 
10 per million 
Posterior Urethral Valves 1 per 10,000 
 
Table 3.  Considerations for the Cause of C3 Glomerulonephritis  
Genetic Mutations C3, CD46 (membrane cofactor protein), CFB, 
CFH, CFHR1, CFHR2, CFHR3, CFHR4, 
CFHR5, CFI 
Autoantibodies C3 nephritic factor (anti-complement factor 
C3bBb), anti-complement factor H, anti-
complement factor B, anti-complement factor 
C3b 
 
A standard and effective treatment is not available (Table 4).  A coherent argument can be 
made for targeting autoantibody (C3NF) generation and/or utilizing drugs and procedures (such 
as therapeutic plasma exchange) that dampen the alternative pathway activity.5,6  Assessing the 
efficacy of any one therapy is difficult due to the inclusion of patients with membranoproliferative 
glomerulonephritis type 1 (which includes both C3 glomerulonephritis and immunoglobulin and 
immune complex glomerulonephritis) in many studies.5 Further, reports of efficacy from 
single/small case series show promising results but are subject to publication bias with the non-
responders never reported.   
Table 4. Considerations for the Treatment of C3 Glomerulopathies: Dense Deposit Disease 
versus C3 Glomerulonephritis. 
Therapy Dense Deposit Disease C3 Glomerulonephritis 
Glucocorticoids No benefit Possible benefit 
Eculizumab Possible benefit Possible benefit 
Plasma Exchange Possible benefit Possible benefit 
Plasma Infusion Possible benefit No experience reported 
Calcinuerin Inhibitors No benefit Possible benefit 
Mycophenolate Mofetil No benefit Possible benefit 
Rituximab No benefit Possible benefit 
 
Greater awareness of this “new” disease entity will facilitate diagnosis and potential 
enrollment in study registries and prospective studies evaluating differentiating clinical 
parameters and therapies.  Due to the rareness of C3Gn, this approach will be necessary to 
help inform best clinical practice.   
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